NEW YORK, Aug. 23, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a private biopharmaceutical company that develops innovative targeted radio-immunotherapeutics, announced that the Company strengthened the management team with the hiring of Jack V. Talley as President and Chief Executive Officer and Enza Guagenti as Chief Financial Officer.
Mr. Talley is a pharmaceutical industry veteran with more than thirty years of experience in marketing, drug development and regulatory matters. He is responsible for guiding two prior companies through the transition to becoming public reporting entities, Penwest Pharmaceuticals and EpiCept Corp. where until recently he served as President and Chief Executive Officer. Additionally, he oversaw the approval of Ceplene for the remission maintenance of acute myeloid leukemia in the European Union as well as its license and eventual sale to Meda AB.
Ms. Guagenti is a CPA with over twenty-five years experience in health care management financial oversight. Prior to assuming the role of CFO, Ms. Guagenti worked for API as a corporate accounting consultant for the past eight years. Ms. Guagenti has held senior management level positions for various companies which includes an out-patient surgery center servicing approximately 8,000 patients per year. She was responsible for operational and financial oversight and reporting as well as compliance with state and federal regulatory bodies. Ms. Guagenti has served as president of the NJ Assoc. of Ambulatory Surgery Centers and has served on various state healthcare committees.
Dragan Cicic, MD will continue with the Company as Chief Operating Officer and Chief Medical Officer.
"We welcome Jack Talley as the CEO of Actinium and are pleased that the Company has strengthened its senior management. The contributions of seasoned executives like Jack and Enza will prove to be extremely valuable in the days ahead as Actinium prepares to raise additional capital and list on the public stock markets in the fall of this year" read a statement prepared by the Board of Directors.
"I am delighted to join Actinium at this pivotal moment in the Company's history", commented Mr. Talley. "Actinium is supported by world class science and a distinguished roster of key hematology opinion leaders that I am delighted to work with. We will continue the ongoing work to improve upon the outcomes of patients suffering from acute myeloid leukemia, one of the most deadly forms of cancer yet with few effective therapies. The recent addition of Iomab-B to Actinium's product portfolio greatly strengthens the prospects for success for the Company".
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a U.S. based biopharmaceutical company that develops innovative targeted payload immunotherapeutics to treat various cancers. The Companies Alpha Particle Immunotherapy Technology platform couples monoclonal antibodies with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular Actinium 225 and Bismuth 213. The final drug construct is designed to specifically target and kill cancer cells while minimizing side effects. Alpha emitters are the most powerful killing agents in existence, with a single atom capable of destroying a cancer cell. At the same time, they do not damage surrounding healthy tissues. API's technology and products are protected by an extensive intellectual property estate of 68 patents - 17 U.S. and 51 International.
Actinium Pharmaceuticals has two clinical stage lead drug candidates for the treatment of blood borne cancers. These lead products have been tested in approximately 300 patients in Phase I and II clinical trials: Its Actimab-A drug candidate is in a company sponsored Phase I/II clinical trial in patients with acute myeloid leukemia over the age of 60. The Company is also developing Iomab-B indicated for the conditioning of bone marrow in order to prepare patients with certain blood cancers for hematopoietic stem cell transplantation. API will sponsor pivotal clinical trials of Iomab-B as the next step towards seeking commercial approval. Approximately a dozen Phase I/II clinical trials are underway under physician IND's for Actinium's lead products. In addition, the Company also has a robust pre-clinical pipeline that the company intends to progress into clinical trials in the next twelve to eighteen months.
For more information:
Visit our web site www.actiniumpharmaceuticals.com or Contact:
Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
|SOURCE Actinium Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved